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doi:10.101Monitoring and Preemptive Rituximab Therapy for
Epstein-Barr Virus Reactivation after Antithymocyte
Globulin Containing Nonmyeloablative Conditioning
for Umbilical Cord Blood Transplantation
Anne H. Blaes,1,2 Qing Cao,1 John E. Wagner,1,3 Jo-Anne H. Young,1,4 Daniel J. Weisdorf,1,2
Claudio G. Brunstein1,2Epstein Barr viremia (EBV) and posttransplantation lymphoproliferative disorder (PTLD) are complications
of hematopoietic stem cell transplantation (HSCT). The use of antithymocyte globulin (ATG) in recipients of
umbilical cord HSCT is a known risk factor for the development of PTLD. In this high-risk population, we
implemented an EBVmonitoring programwith preemptive therapy with rituximab (375 mg/m2 intravenously
[i.v.]) for EBV viremia (.1000 copies/mL). Eight of 35 patients treated with a UCB HSCT between 2007 and
2009, developed EBV viremia. Two of 7 developed PTLD (with 1 of the 2 dying of PTLD), despite prophylactic
rituximab use. When compared with our previously described cohort where 6 of 30 developed EBV viremia
and 5 of 6 patients developed PTLD (with 2 of 5 dying of PTLD), the incidence of PTLD appears to be less
when prophylactic rituximab is administered. Despite small numbers, our observations suggest that in this
high-risk population, EBV monitoring accompanied by preemptive therapy may reduce the risk of progres-
sion to life-threatening PTLD; further follow-up of this cohort and a larger multi-institutional prospective
study of this preemptive strategy is warranted.
Biol Blood Marrow Transplant 16: 287-291 (2010)  2010 Published by Elsevier Inc.KEY WORDS: MMF, Pediatric, Pharmacokinetics, Allo SCTINTRODUCTION
Epstein Barr virus (EBV) reactivation and post-
transplantation lymphoproliferative disorder (PTLD)
are complications of allogeneic hematopoietic stem
cell transplantation (HSCT) [1-6]. In HSCT recipi-
ents, the reported incidence can vary from 0.4% to
24% [7,8]. The biggest risk factors for PTLD after
HSCT are T cell depletion, HLA disparity, use of
antithymocyte globulin (ATG), and grade III/IV
graft-versus-host disease (GVHD). There have also
been reports of an increased incidence of PTLD in
subsets of patients who have received an umbilical1University of Minnesota Blood and Marrow Transplant
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6/j.bbmt.2009.10.008cord blood transplantation (UCBT) [6,9-11]. In these
reports, however, most of these patients had received
ATG as part of their preparatory regimen.
High titer EBV viremia detected by quantitative
polymerase chain reaction (qPCR) may be predictive
of the development of PTLD [12,13]. EBV viral load
monitoring and preemptive therapy with anti-CD20 an-
tibodies may be 1 approach in reducing the incidence of
PTLD [14-20]. We previously reported a high inci-
dence of EBV viremia for recipients of an ATG-contain-
ing nonmyeloablative (MA) UCB [6]. Here, we report
the incidence and outcomes of EBV-related complica-
tions since we implemented an EBV monitoring pro-
gram with preemptive therapy for this patient subset.PATIENTS AND METHODS
In January 2007, we instituted a monitoring proto-
col for all patients at our institution receiving an
ATG-containing nonmyeloablative (NMA) UCB
HSCT. The preparatory regimen consisted of a single
dose of cyclophosphamide (Cy) 50 mg/kg intravenously
(i.v.) on day –6, fludarabine (Flu) 40 mg/m2 i.v. daily on
days –6 to –2, a single fraction of total body irradiation287
288 Biol Blood Marrow Transplant 16:287-291, 2010A. H. Blaes et al.(TBI) 200 cGy without shielding on day –1, and equine
ATG (ATGAM, Pharmacia, Kalamazoo, MI) at 15 mg/
kg i.v. every 12 hours on days26 to24. Graft selection,
posttransplantation immunosuppression, GVHD ther-
apy, and antiviral prophylaxis/supportive care after
UCB have been previously described [19].EBV Monitoring and Complication Definitions
Patients were monitored with on-site serial qEBV
PCR testing on whole blood using real-time TaqMan
PCR every 2 weeks between days130 and1180 post-
UCBT. The amplicon was a 71-bp portion of the
Ebna1 gene. qEBV results were reported as viral cop-
ies per milliliter (mL). The limit of detection of the as-
say was 10 viral copies/reaction [21]. EBV viremia was
defined as more than 1000 copies of EBV DNA/mL of
whole blood on 1 occasion. EBV PTLD was defined as
biopsy proven PTLD with positivity for in situ hybrid-
ization by Epstein Barr early response (EBER) stain-
ing, regardless of the presence of viremia.Preemptive Therapy Strategy
In the event of EBV viremia, patients underwent
CT scan imaging to determine whether adenopathy
was present; palpable or radiographic adenopathy led
to a biopsy whenever possible. At the time of EBV
viremia, patients received 1 dose of rituximab (RTX)
375 mg/m2 i.v. (Genentech, Inc., South San Francisco,
CA). All patients had hepatitis B serologies tested
before HSCT, and no patient had an active hepatitis
B viremia at the time RTX was started. Patients
with EBV viremia were monitored weekly to follow
response to RTX. For patients with a decrease in
EBV viremia titer following 1 dose of rituximab, viral
loads were monitored weekly to follow response toTable 1. Demographic Characteristics of EBV-Monitored Patients
Factors Historic Cont
Number of patients 30
Median age (year) 55 (19-69)
Median weight (kg) 85 (50-134)
CMV-positive recipients 12 (40%)
Median infused nucleated cell dose 108/kg 0.35 (0.21-0.6
Median infused CD34+ cell dose 10 6/kg 0.44 (0.07-1.6
Median time to follow-up (day) 219 (7-1056)
HLA match (worst match)
6 of 6 0
5 of 6 0
4 of 6 30 (100%)
No. of UCB recipients (%)
Single unit 1 (3%)
Double unit 29 (97%)
No. with malignant diagnosis at Tx (%) 28 (93%)
EBV subgroups 6
Viremia 1 (3%)
PTLD 5 (17%)
EBV indicates Epstein-Barr virus; PTLD, posttransplantation lymphoproliferati
‘P values for the comparison of categoric and continuous variables were p
respectively.RTX. For patients with persistent viremia or patho-
logic evidence of PTLD, additional weekly doses of
RTX were administered until resolution of the viremia.
Whenever possible, immunosuppression was tapered.
All HSCT protocols and this analysis were approved
by the University of Minnesota institutional review board
and registered at www.clinicaltrials.gov (NCT00365287,
closed, and NCT00305682). All patients or their legal
guardians provided written informed consent according
to the Declaration of Helsinki.RESULTS
Thirty-five consecutive patients who received
a UCBT with this uniform ATG containing NMA
regimen at the University of Minnesota between Janu-
ary 2007 and 2009, were included in this analysis.
Eight of 35 patients (23%) developed EBV viremia
in 2 cases associated with PTLD. The demographic
characteristics of the current cohort were compared
to the high-risk group of recipients previously re-
ported [6] who also received an NMA ATG containing
UCBT. The results are summarized in Table 1.
The characteristics of our current cohort that
developed EBV-related complications are described
in Table 2. In our current cohort, the patients had
a median age of 60 years (range: 36-68 years), median
weight of 84 kg (range: 69-101 kg), and a median
follow-up of 349 days (range: 31-403 days). All
received 2 unit UCB grafts. Their median infused total
nucleated cell dose was 0.35 108/kg (range: 0.29-
0.40) with a median CD34 cell dose of 0.37 106/kg
(0.14-1.32). The median time from transplantation
to EBV viremia was 83 days (range: 71-342). Median
peak EBV viremia was 31,500 copies (range: 3,100-Compared to Historic Controls
rols Current Cohort P-Value
34 NA
56 (36-67) .24
80 (52-111) .08
24 (71%) .02
8) 0.35 (0.22-0.59) .94
6) 0.38 (0.14-1.32) .27
339 (31-765) .59
<.01
1 (3%)
16 (47%)
17 (50%)
1.00
2 (6%)
32 (94%)
33 (97%) .60
8 .10
6 (18%)
2 (6%)
ve disorder; CMV, cytomegalovirus.
erformed from the Fisher’s exact test and wilcoxon singed rank test,
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Biol Blood Marrow Transplant 16:287-291, 2010 289EBV Monitoring and Preemptive Therapy in UCBT311,300). Patient 4 had a qPCR titer of 3,100 copies
243 days posttransplantation, yet EBV viremia
resolved without treatment. At the time of initial reac-
tivation at 1300 copies, the patient’s immunosuppres-
sion was decreased. The patient’s viremia initially
became undetectable and then increased to 3100
copies. Given the low titers for EBV reactivation and
the interval from transplantation, the treating physi-
cian felt it was not clinically necessary to treat with pre-
emptive rituximab. The EBV viremia subsequently
resolved, and the patient remains alive over 300 days
posttransplant.
Seven patients were preemptively treated with
RTX for a median of 3 weekly doses (Table 2). Two
of these patients (6%) had EBV-viremia associated
with PTLD. Patient 1 had PTLD on his left tonsil,
and underwent a tonsillectomy and received 4 weekly
doses of RTX; he remains in complete remission
(CR) now 1 year post-UCB HSCT. Patient 7 devel-
oped EBV-viremia and biopsy-proven PTLD of the
lung. Despite 7 weekly doses of RTX and a decrease
in immunosuppression, the patient with PTLD died
of progressive disease.DISCUSSION
EBV reactivation and PTLD are complications of
UCBT, particularly when ATG is used in the prepara-
tory regimen [6,11]. Based on our previously published
report in which there was a high incidence of EBV vi-
remia in recipients of an ATG containing NMA UCB
HSCT, we implemented an EBV monitoring program
with preemptive therapy for this patient subset. Com-
pared to our historic cohort, our current cohort re-
ceived better HLA-matched grafts. There were
similar rates of EBV-related complications. However,
in the historic cohort without EBV monitoring, 5 of 6
with EBV reactivation developed PTLD with 2 deaths,
in contrast to 2 of 8 PTLDs in the current cohort with
1 related death. Despite small numbers, our observa-
tions suggest that, in this high risk population, EBV-
monitoring accompanied by preemptive therapy may
reduce the risk of progression to life-threatening
PTLD [14-18].
The options to treat EBV complications, in partic-
ular, PTLD, which often presents with disseminated
disease and early, rapid organ dysfunction [22] after
UCB HSCT are more limited than after non-UCB
HSCT. Whereas immunosuppression can be tapered
and patients may be given anti-CD20 antibodies
and/or chemotherapy, there are no donor lymphocytes
available from cord donor sources [23]. It is possible
that, in the future, with the availability of EBV specific
cytotoxic T cell-lymphocytes [24] or UCB-derived ex
vivo expanded T cells [25], this limitation may be over-
come. An alternative strategy would be prophylactic
290 Biol Blood Marrow Transplant 16:287-291, 2010A. H. Blaes et al.RTX for high-risk patients such as those receiving
ATG or T cell-depleted grafts [26]. Although prelim-
inary data suggest this approach may reduce the risk of
PTLD, prophylactic RTX would be associated with
greater cost and risk of adverse events. Therefore, at
present, a low threshold to start preemptive therapy
seems justified to prevent progression from EBV-
viremia to PTLD that, once established, has a poor
prognosis [10].
Typically, HSCT recipients will develop PTLD
early, at a median of 2 to 3 months after HSCT [22].
Two of our patients developed EBV complications
beyond the planned 180 day window of monitoring
at which time they were hospitalized for mental status
changes (patient 4) and hypoxia (patient 6), respec-
tively, resulting in the detection of EBV viremia (Table
2). Still, 6 of 8 patients developed EBV viremia within
180 days, as did most patients in our historic cohort
[6]. EBV-viremia qPCR monitoring is costly. There-
fore, any monitoring strategy needs to consider the
risk and timing of EBV complications and the cost of
prophylactic RTX [21].
In the event of a pathologic diagnosis of PTLD as
opposed to isolated EBV-viremia, RTX therapy alone
may not be able to eradicate rapidly growing PTLD.
Immunosuppression must be reduced whenever possi-
ble, and the addition of more conventional chemother-
apy agents should be considered even though these
agents may yield excess myelosuppression and greater
toxicity.
Our results, with an incidence of PTLD now simi-
lar to other settings of UCBT [5,6], support EBV
monitoring to day 180 and preemptive therapy for
patients undergoing an ATG-containing NMA UCB
HSCT. Although there are limited data on the appro-
priate threshold to give preemptive therapy [14-18]
and spontaneous remissions of viremia can occur, our
EBV-viremia treatment threshold level and length of
monitoring are covering our high-risk population dur-
ing a period in which there is a greater risk of EBV-re-
lated complications. Our preliminary data suggests
a reduction in the risk of progression to PTLD. How-
ever, to draw more definitive conclusions, further fol-
low-up of the current cohort and larger prospective
multi-institutional studies to assure adequate numbers
of patients are warranted.ACKNOWLEDGMENTS
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